Design, Synthesis, and Anticancer Activity of Novel Enmein-Type Diterpenoid Derivatives Targeting the PI3K/Akt/mTOR Signaling Pathway.

Jiafeng Wang, Lu Wang, Yingbo Zhang, Siwen Pan, Yu Lin, Jiale Wu, Ming Bu

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiafeng WangCollege of Pathology, Qiqihar Medical University, Qiqihar 161006, China.

Lu WangCollege of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.

Yingbo ZhangCollege of Pathology, Qiqihar Medical University, Qiqihar 161006, China.

Siwen PanCollege of Pathology, Qiqihar Medical University, Qiqihar 161006, China.ORCID 0009-0008-8200-7818

Yu LinCollege of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.

Jiale WuCollege of Life and Health, Hainan University, Haikou 570228, China.

Ming BuCollege of Pharmacy, Qiqihar Medical University, Qiqihar 161006, China.ORCID 0000-0001-9752-0886

Funding

the Fundamental Research Funds for Education Department of Heilongjiang Province of China 2022-KYYWF-0787the Natural Science Foundation of Heilongjiang Province of China LH2022H113

6 · The paper itself

Abstract

The enmein-type diterpenoids are a class of anticancer

Indexed as

Antineoplastic AgentsApoptosisCell ProliferationDiterpenesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesA549 CellsCell Line, TumorDrug DesignHumansReactive Oxygen SpeciesStructure-Activity RelationshipAntineoplastic AgentsDiterpenesenmeinMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesTOR Serine-Threonine Kinasesanticancerderivativesenmein-type ent-KauranesPI3K/Akt/mTOR pathwaystructural modification

Identifiers

PMID39274913

DOI10.3390/molecules29174066

PMCPMC11396751

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.